308 results on '"Pallisgaard, Jannik"'
Search Results
2. Management of Atrial Fibrillation in Older Patients by Morbidity Burden: Insights From Get With The Guidelines‐Atrial Fibrillation
- Author
-
Dalgaard, Frederik, Xu, Haolin, Matsouaka, Roland A, Russo, Andrea M, Curtis, Anne B, Rasmussen, Peter Vibe, Ruwald, Martin H, Fonarow, Gregg C, Lowenstern, Angela, Hansen, Morten L, Pallisgaard, Jannik L, Alexander, Karen P, Alexander, John H, Lopes, Renato D, Granger, Christopher B, Lewis, William R, Piccini, Jonathan P, and Al‐Khatib, Sana M
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Aging ,Cardiovascular ,Heart Disease ,Clinical Research ,Management of diseases and conditions ,7.1 Individual care needs ,Administration ,Oral ,Age Factors ,Aged ,Aged ,80 and over ,Anticoagulants ,Atrial Fibrillation ,Cross-Sectional Studies ,Female ,Hospitalization ,Humans ,Logistic Models ,Male ,Multimorbidity ,Odds Ratio ,Practice Guidelines as Topic ,Practice Patterns ,Physicians' ,Registries ,anticoagulation ,atrial fibrillation ,comorbidities ,multimorbidity ,oral anticoagulants ,prescription ,quality of care ,Cardiorespiratory Medicine and Haematology ,Cardiovascular medicine and haematology - Abstract
Background Knowledge is scarce regarding how multimorbidity is associated with therapeutic decisions regarding oral anticoagulants (OACs) in patients with atrial fibrillation. Methods and Results We conducted a cross-sectional study of hospitalized patients with atrial fibrillation using the Get With The Guidelines-Atrial Fibrillation registry from 2013 to 2019. We identified patients ≥65 years and eligible for OAC therapy. Using 16 available comorbidity categories, patients were stratified by morbidity burden. A multivariable logistic regression model was used to determine the odds of receiving OAC prescription at discharge by morbidity burden. We included 34 174 patients with a median (interquartile range) age of 76 (71-83) years, 56.6% women, and 41.9% were not anticoagulated at admission. Of these patients, 38.6% had 0 to 2 comorbidities, 50.7% had 3 to 5 comorbidities, and 10.7% had ≥6 comorbidities. The overall discharge OAC prescription was high (85.6%). The prevalence of patients with multimorbidity increased from 59.7% in 2014 to 64.3% in 2019 (P trend=0.002). Using 0 to 2 comorbidities as the reference, the adjusted odds ratio (95% CI) of OAC prescription were 0.93 (0.82, 1.05) for patients with 3 to 5 comorbidities and 0.72 (0.60, 0.86) for patients with ≥6 comorbidities. In those with ≥6 comorbidities, the most common reason for nonprescription of OACs were frequent falls/frailty (31.0%). Conclusions In a contemporary quality-of-care database of hospitalized patients with atrial fibrillation eligible for OAC therapy, multimorbidity was common. A higher morbidity burden was associated with a lower odds of OAC prescription. This highlights the need for interventions to improve adherence to guideline-recommended anticoagulation in multimorbid patients with atrial fibrillation.
- Published
- 2020
3. Lung ultrasound findings in hospitalized COVID-19 patients in relation to venous thromboembolic events: the ECHOVID-19 study
- Author
-
Skaarup, Kristoffer Grundtvig, Lassen, Mats Christian Højbjerg, Espersen, Caroline, Lind, Jannie Nørgaard, Johansen, Niklas Dyrby, Sengeløv, Morten, Alhakak, Alia Saed, Nielsen, Anne Bjerg, Ravnkilde, Kirstine, Hauser, Raphael, Schöps, Liv Borum, Holt, Eva, Bundgaard, Henning, Hassager, Christian, Jabbari, Reza, Carlsen, Jørn, Kirk, Ole, Bodtger, Uffe, Lindholm, Matias Greve, Wiese, Lothar, Kristiansen, Ole Peter, Walsted, Emil Schwarz, Nielsen, Olav Wendelboe, Lindegaard, Birgitte, Tønder, Niels, Jeschke, Klaus Nielsen, Ulrik, Charlotte Suppli, Lamberts, Morten, Sivapalan, Pradeesh, Pallisgaard, Jannik, Gislason, Gunnar, Iversen, Kasper, Jensen, Jens Ulrik Stæhr, Schou, Morten, Skaarup, Søren Helbo, Platz, Elke, and Biering-Sørensen, Tor
- Published
- 2022
- Full Text
- View/download PDF
4. Electrical cardioversion of atrial fibrillation and the risk of brady-arrhythmic events
- Author
-
Rasmussen, Peter Vibe, Blanche, Paul, Dalgaard, Frederik, Gislason, Gunnar Hilmar, Torp-Pedersen, Christian, Tønnesen, Jacob, Ruwald, Martin H., Pallisgaard, Jannik Langtved, and Hansen, Morten Lock
- Published
- 2022
- Full Text
- View/download PDF
5. Lower Recurrence Rates of Atrial Fibrillation and MACE Events After Early Compared to Late Ablation: A Danish Nationwide Register Study
- Author
-
Tønnesen, Jacob, primary, Ruwald, Martin H., additional, Pallisgaard, Jannik, additional, Rasmussen, Peter Vibe, additional, Johannessen, Arne, additional, Hansen, Jim, additional, Worck, Rene H., additional, Zörner, Christopher R., additional, Riis‐Vestergaard, Lise, additional, Middelfart, Charlotte, additional, Sørensen, Samuel K., additional, Sattler, Stefan, additional, Gislason, Gunnar, additional, and Hansen, Morten Lock, additional
- Published
- 2024
- Full Text
- View/download PDF
6. Lower Recurrence Rates of Atrial Fibrillation and MACE Events After Early Compared to Late Ablation:A Danish Nationwide Register Study
- Author
-
Tønnesen, Jacob, Ruwald, Martin H., Pallisgaard, Jannik, Rasmussen, Peter Vibe, Johannessen, Arne, Hansen, Jim, Worck, Rene H., Zörner, Christopher R., Riis-Vestergaard, Lise, Middelfart, Charlotte, Sørensen, Samuel K., Sattler, Stefan, Gislason, Gunnar, Hansen, Morten Lock, Tønnesen, Jacob, Ruwald, Martin H., Pallisgaard, Jannik, Rasmussen, Peter Vibe, Johannessen, Arne, Hansen, Jim, Worck, Rene H., Zörner, Christopher R., Riis-Vestergaard, Lise, Middelfart, Charlotte, Sørensen, Samuel K., Sattler, Stefan, Gislason, Gunnar, and Hansen, Morten Lock
- Abstract
Background Guidelines recommend prioritizing treatment with antiarrhythmic drugs before referral of patients with atrial fibrillation to ablation, delaying a potential subsequent ablation. However, delaying ablation may affect ablation outcomes. We sought to investigate the impact of duration from diagnosis to ablation on the risk of atrial fibrillation recurrence and adverse events. Methods and Results Using Danish nationwide registries, all patients with first‐time ablation for atrial fibrillation were identified and included from 2010 to 2018. Patients were divided into 4 groups by diagnosis‐to‐ablation time: <1.0 year (early ablation), 1.0 to 1.9 years, 2.0 to 2.9 years, and >2.9 years (late ablation). The primary end point was atrial fibrillation recurrence after the 90‐day blanking period, defined by admission for atrial fibrillation, cardioversions, use of antiarrhythmic drugs, or repeat atrial fibrillation ablations. The secondary end point was a composite end point of heart failure, ischemic stroke, or death, and each event individually. The study cohort consisted of 7705 patients. The 5‐year cumulative incidence of atrial fibrillation recurrence in the 4 groups was 42.9%, 54.8%, 55.9%, and 58.4%, respectively. Hazard ratios were 1.20 (95% CI, 1.07–1.35), 1.29 (95% CI, 1.13–1.47), and 1.40 (95% CI, 1.28–1.53), respectively, with the early ablation group as reference. The hazard ratio for the combined secondary end point was 1.22 (95% CI, 1.04–1.44) in the late ablation group compared with the early ablation group. Conclusions In patients undergoing ablation for atrial fibrillation, early ablation was associated with a significantly lower risk of atrial fibrillation recurrence. Furthermore, the associated risk of heart failure, ischemic stroke, or death was significantly lower in early‐compared with late‐ablation patients., BACKGROUND: Guidelines recommend prioritizing treatment with antiarrhythmic drugs before referral of patients with atrial fibrillation to ablation, delaying a potential subsequent ablation. However, delaying ablation may affect ablation outcomes. We sought to investigate the impact of duration from diagnosis to ablation on the risk of atrial fibrillation recurrence and adverse events. METHODS AND RESULTS: Using Danish nationwide registries, all patients with first-time ablation for atrial fibrillation were identified and included from 2010 to 2018. Patients were divided into 4 groups by diagnosis-to-ablation time: <1.0 year (early ablation), 1.0 to 1.9 years, 2.0 to 2.9 years, and >2.9 years (late ablation). The primary end point was atrial fibrillation recurrence after the 90-day blanking period, defined by admission for atrial fibrillation, cardioversions, use of antiarrhythmic drugs, or repeat atrial fibrillation ablations. The secondary end point was a composite end point of heart failure, ischemic stroke, or death, and each event individually. The study cohort consisted of 7705 patients. The 5-year cumulative incidence of atrial fibrillation recurrence in the 4 groups was 42.9%, 54.8%, 55.9%, and 58.4%, respectively. Hazard ratios were 1.20 (95% CI, 1.07-1.35), 1.29 (95% CI, 1.13-1.47), and 1.40 (95% CI, 1.28-1.53), respectively, with the early ablation group as reference. The hazard ratio for the combined secondary end point was 1.22 (95% CI, 1.04-1.44) in the late ablation group compared with the early ablation group. CONCLUSIONS: In patients undergoing ablation for atrial fibrillation, early ablation was associated with a significantly lower risk of atrial fibrillation recurrence. Furthermore, the associated risk of heart failure, ischemic stroke, or death was significantly lower in early-compared with late-ablation patients.
- Published
- 2024
7. Serial troponin-I and long-term outcomes in subjects with suspected acute coronary syndrome
- Author
-
Pareek, Manan, Kristensen, Anna Meta Dyrvig, Vaduganathan, Muthiah, Byrne, Christina, Biering-Sørensen, Tor, Højbjerg Lassen, Mats Christian, Johansen, Niklas Dyrby, Skaarup, Kristoffer Grundtvig, Rosberg, Victoria, Pallisgaard, Jannik L., Mortensen, Martin Bødtker, Maeng, Michael, Polcwiartek, Christoffer B., Frangeskos, Julia, McCarthy, Cian P., Bonde, Anders Nissen, Lee, Christina Ji Young, Fosbøl, Emil L., Køber, Lars, Olsen, Niels Thue, Gislason, Gunnar H., Torp-Pedersen, Christian, Bhatt, Deepak L., Kragholm, Kristian H., Pareek, Manan, Kristensen, Anna Meta Dyrvig, Vaduganathan, Muthiah, Byrne, Christina, Biering-Sørensen, Tor, Højbjerg Lassen, Mats Christian, Johansen, Niklas Dyrby, Skaarup, Kristoffer Grundtvig, Rosberg, Victoria, Pallisgaard, Jannik L., Mortensen, Martin Bødtker, Maeng, Michael, Polcwiartek, Christoffer B., Frangeskos, Julia, McCarthy, Cian P., Bonde, Anders Nissen, Lee, Christina Ji Young, Fosbøl, Emil L., Køber, Lars, Olsen, Niels Thue, Gislason, Gunnar H., Torp-Pedersen, Christian, Bhatt, Deepak L., and Kragholm, Kristian H.
- Abstract
Aims: It is unclear how serial high-sensitivity troponin-I (hsTnI) concentrations affect long-term prognosis in individuals with suspected acute coronary syndrome (ACS). Methods and results: Subjects who underwent two hsTnI measurements (Siemens TnI Flex® Reagent) separated by 1-7 h, during a first-time hospitalization for myocardial infarction, unstable angina, observation for suspected myocardial infarction, or chest pain from 2012 through 2019, were identified through Danish national registries. Individuals were stratified per their hsTnI concentration pattern (normal, rising, persistently elevated, or falling) and the magnitude of hsTnI concentration change (<20%, >20-50%, or >50% in either direction). We calculated absolute and relative mortality risks standardized to the distributions of risk factors for the entire study population. A total of 20 609 individuals were included of whom 2.3% had died at 30 days, and an additional 4.7% had died at 365 days. The standardized risk of death was highest among persons with a persistently elevated hsTnI concentration (0-30 days: 8.0%, 31-365 days: 11.1%) and lowest among those with two normal hsTnI concentrations (0-30 days: 0.5%, 31-365 days: 2.6%). In neither case did relative hsTnI concentration changes between measurements clearly affect mortality risk. Among persons with a rising hsTnI concentration pattern, 30-day mortality was higher in subjects with a >50% rise compared with those with a less pronounced rise (2.2% vs. <0.1%). Conclusion: Among individuals with suspected ACS, those with a persistently elevated hsTnI concentration consistently had the highest risk of death. In subjects with two normal hsTnI concentrations, mortality was very low and not affected by the magnitude of change between measurements.
- Published
- 2024
8. Significance of early recurrence of atrial fibrillation after catheter ablation: a nationwide Danish cohort study
- Author
-
Hodges, Gethin, Bang, Casper N., Torp-Pedersen, Christian, Hansen, Morten Lock, Schjerning, Anne-Marie, Hansen, Jim, Johannessen, Arne, Gislason, Gunnar H., and Pallisgaard, Jannik
- Published
- 2021
- Full Text
- View/download PDF
9. Amiodarone treatment in atrial fibrillation and the risk of incident cancers: A nationwide observational study
- Author
-
Rasmussen, Peter Vibe, Dalgaard, Frederik, Hilmar Gislason, Gunnar, Torp-Pedersen, Christian, Piccini, Jonathan, D’Souza, Maria, Ruwald, Martin H., Pallisgaard, Jannik Langtved, and Hansen, Morten Lock
- Published
- 2020
- Full Text
- View/download PDF
10. Serial troponin-I and long-term outcomes in subjects with suspected acute coronary syndrome
- Author
-
Pareek, Manan, primary, Kristensen, Anna Meta Dyrvig, additional, Vaduganathan, Muthiah, additional, Byrne, Christina, additional, Biering-Sørensen, Tor, additional, Højbjerg Lassen, Mats Christian, additional, Johansen, Niklas Dyrby, additional, Skaarup, Kristoffer Grundtvig, additional, Rosberg, Victoria, additional, Pallisgaard, Jannik L, additional, Mortensen, Martin Bødtker, additional, Maeng, Michael, additional, Polcwiartek, Christoffer B, additional, Frangeskos, Julia, additional, McCarthy, Cian P, additional, Bonde, Anders Nissen, additional, Lee, Christina Ji-Young, additional, Fosbøl, Emil L, additional, Køber, Lars, additional, Olsen, Niels Thue, additional, Gislason, Gunnar H, additional, Torp-Pedersen, Christian, additional, Bhatt, Deepak L, additional, and Kragholm, Kristian H, additional
- Published
- 2023
- Full Text
- View/download PDF
11. Rate and rhythm therapy in patients with atrial fibrillation and the risk of pacing and bradyarrhythmia
- Author
-
Dalgaard, Frederik, Pallisgaard, Jannik L., Lindhardt, Tommi Bo, Torp-Pedersen, Christian, Gislason, Gunnar H., and Ruwald, Martin H.
- Published
- 2019
- Full Text
- View/download PDF
12. Temporal trends of hypertrophic cardiomyopathy in Denmark: a nationwide retrospective cohort study
- Author
-
Zörner, Christopher Ryan, primary, Pallisgaard, Jannik, additional, Schjerning, Anne-Marie, additional, Jensen, Morten Kvistholm, additional, Tønnesen, Jacob, additional, Da Riis-Vestergaard, Lise, additional, Middelfart, Charlotte, additional, Rasmussen, Peter Vibe, additional, Gislason, Gunnar, additional, and Hansen, Morten Lock, additional
- Published
- 2023
- Full Text
- View/download PDF
13. Combining Oral Anticoagulants With Platelet Inhibitors in Patients With Atrial Fibrillation and Coronary Disease
- Author
-
Sindet-Pedersen, Caroline, Lamberts, Morten, Staerk, Laila, Nissen Bonde, Anders, Berger, Jeffrey S., Pallisgaard, Jannik Langtved, Lock Hansen, Morten, Torp-Pedersen, Christian, Gislason, Gunnar H., and Olesen, Jonas Bjerring
- Published
- 2018
- Full Text
- View/download PDF
14. Risk of Myocardial Infarction in Anticoagulated Patients With Atrial Fibrillation
- Author
-
Lee, Christina Ji-Young, Gerds, Thomas Alexander, Carlson, Nicholas, Bonde, Anders Nissen, Gislason, Gunnar Hilmar, Lamberts, Morten, Olesen, Jonas Bjerring, Pallisgaard, Jannik Langtved, Hansen, Morten Lock, and Torp-Pedersen, Christian
- Published
- 2018
- Full Text
- View/download PDF
15. Thiazolidinediones and Risk of Atrial Fibrillation Among Patients with Diabetes and Coronary Disease
- Author
-
Pallisgaard, Jannik Langtved, Brooks, Maria Mori, Chaitman, Bernard R., Boothroyd, Derek B., Perez, Marco, and Hlatky, Mark A.
- Published
- 2018
- Full Text
- View/download PDF
16. High-sensitivity cardiac troponin T is superior to troponin I in the prediction of mortality in patients without acute coronary syndrome
- Author
-
Árnadóttir, Ásthildur, Vestergaard, Kirstine Roll, Pallisgaard, Jannik, Sölétormos, György, Steffensen, Rolf, Goetze, Jens P., and Iversen, Kasper
- Published
- 2018
- Full Text
- View/download PDF
17. Out-of-hospital cardiac arrest: Probability of bystander defibrillation relative to distance to nearest automated external defibrillator
- Author
-
Sondergaard, Kathrine B., Hansen, Steen Moller, Pallisgaard, Jannik L., Gerds, Thomas Alexander, Wissenberg, Mads, Karlsson, Lena, Lippert, Freddy K., Gislason, Gunnar H., Torp-Pedersen, Christian, and Folke, Fredrik
- Published
- 2018
- Full Text
- View/download PDF
18. PO-05-185 PREDICTION AND RISK OF ATRIAL FIBRILLATION IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY: A DANISH NATIONWIDE COHORT STUDY
- Author
-
Zörner, Christopher, primary, Pallisgaard, Jannik L., additional, Schjerning, Anne-Marie, additional, Jensen, Morten K., additional, Tønnesen, Jacob, additional, Vestergaard, Lise D., additional, Rasmussen, Peter Vibe, additional, Gislason, Gunnar, additional, and Hansen, Morten L., additional
- Published
- 2023
- Full Text
- View/download PDF
19. Risk and timing of venous thromboembolism in patients with gastrointestinal cancer:A nationwide Danish cohort study
- Author
-
Tønnesen, Jacob, Pallisgaard, Jannik, Rasmussen, Peter Vibe, Ruwald, Martin H., Lamberts, Morten, Nouhravesh, Nina, Strange, Jarl, Gislason, Gunnar Hilmar, Hansen, Morten Lock, Tønnesen, Jacob, Pallisgaard, Jannik, Rasmussen, Peter Vibe, Ruwald, Martin H., Lamberts, Morten, Nouhravesh, Nina, Strange, Jarl, Gislason, Gunnar Hilmar, and Hansen, Morten Lock
- Abstract
Aims Cancer is a well-known risk factor of venous thromboembolism (VTE). Some cancers are believed to be more thrombogenic. The purpose of this study was to investigate the characteristics of patients with incident gastrointestinal cancers (GI) and their associated 1-year risk and timing of venous thromboembolic events and the 1-year mortality. Methods This study was a retrospective cohort study. Through Danish nationwide registries, all patients with first-time GI cancer diagnosis from 2008 to 2018 were identified. Incident VTE events were identified within a 1-year follow-up after GI cancer diagnosis using the Aalen-Johansen estimator. Cox proportional-hazard models were applied to investigate risk factors for VTE events and the impact of VTE on mortality. Results A total of 87 069 patients were included and stratified by cancer types: liver (5.8%), pancreatic (12.0%), gastric (6.9%), small intestinal (1.9%), colorectal (61.8%), oesophageal (7.3%) and gallbladder (3%). Most VTE events happened close to onset of the cancer diagnosis with declining events by time. The 1-year cumulative incidence of VTE differed according to cancer type with pancreatic cancer being most thrombogenic (7.8%), and colorectal and liver cancer being the least (3.6%). Prior VTE, heart failure, chronic obstructive pulmonary disease (COPD), liver disease, chronic kidney disease (CKD) and diabetes increased the VTE risk. Overall, the patients with GI cancer had high 1-year mortality of 33.3% with patients with pancreatic cancer having the highest mortality (70.3%). Conclusion We found that most VTE events happen close to onset of the GI cancer diagnosis and thrombogenicity differed by type of GI cancer, ranging from 7.8% in patients with pancreatic cancer to 3.6% in colorectal and patients with liver cancer. Prior VTE, heart failure, COPD, liver disease, CKD and DM were associated with increased risk of VTE.
- Published
- 2023
20. Atrial fibrillation onset before heart failure or vice versa:what is worst? A nationwide register study
- Author
-
Pallisgaard, Jannik, Greve, Anders M., Lock-Hansen, Morten, Thune, Jens Jakob, Fosboel, Emil Loldrup, Devereux, Richard B., Okin, Peter M., Gislason, Gunnar H., Torp-Pedersen, Christian, Bang, Casper N., Pallisgaard, Jannik, Greve, Anders M., Lock-Hansen, Morten, Thune, Jens Jakob, Fosboel, Emil Loldrup, Devereux, Richard B., Okin, Peter M., Gislason, Gunnar H., Torp-Pedersen, Christian, and Bang, Casper N.
- Abstract
Aims Atrial fibrillation (AF) and heart failure (HF) often coexist. However, whether AF onset before HF or vice versa is associated with the worst outcome remains unclear. A consensus of large studies can guide future research and preventive strategies to better target high-risk patients. Methods and results We included all Danish cases with the coexistence of AF and HF (2005–17) using nationwide registries. Patients were divided into three separate groups (i) AF before HF, (ii) HF before AF, or (iii) AF and HF diagnosed concurrently (±30 days). Adjusting landmark Cox analyses (index date was the time of the latter diagnosis of AF or HF) were used for evaluating the association of the three groups with a composite outcome of ischaemic stroke or death. Among a total of 49 042 patients included, 40% had AF before HF, 27% had HF before AF, and 33% had AF and HF diagnosed concurrently. The composite endpoint accrued more often in patients with HF before AF compared to the two other groups (<0.001), and this remained significant in the adjusted analyses with hazard ratios (95% confidence intervals) of 1.26 (1.22–1.30) compared to AF before HF. Finally, antihypertensive treatment, oral anticoagulants, amiodarone, statins, and AF ablation were associated with a lower hazard ratio of the composite endpoint (all < 0.001). Conclusions In this large Danish national cohort, diagnosis of HF before AF was associated with an increased absolute risk of death compared to AF before HF and AF and HF diagnosed concurrently. Antihypertensive treatment, oral anticoagulants, amiodarone, statins, and AF ablation may improve prognosis., Aims: Atrial fibrillation (AF) and heart failure (HF) often coexist. However, whether AF onset before HF or vice versa is associated with the worst outcome remains unclear. A consensus of large studies can guide future research and preventive strategies to better target high-risk patients. Methods and results: We included all Danish cases with the coexistence of AF and HF (2005-17) using nationwide registries. Patients were divided into three separate groups (i) AF before HF, (ii) HF before AF, or (iii) AF and HF diagnosed concurrently (±30 days). Adjusting landmark Cox analyses (index date was the time of the latter diagnosis of AF or HF) were used for evaluating the association of the three groups with a composite outcome of ischaemic stroke or death. Among a total of 49 042 patients included, 40% had AF before HF, 27% had HF before AF, and 33% had AF and HF diagnosed concurrently. The composite endpoint accrued more often in patients with HF before AF compared to the two other groups (<0.001), and this remained significant in the adjusted analyses with hazard ratios (95% confidence intervals) of 1.26 (1.22-1.30) compared to AF before HF. Finally, antihypertensive treatment, oral anticoagulants, amiodarone, statins, and AF ablation were associated with a lower hazard ratio of the composite endpoint (all < 0.001). Conclusions: In this large Danish national cohort, diagnosis of HF before AF was associated with an increased absolute risk of death compared to AF before HF and AF and HF diagnosed concurrently. Antihypertensive treatment, oral anticoagulants, amiodarone, statins, and AF ablation may improve prognosis.
- Published
- 2023
21. Short- and long-term risk of atrial fibrillation recurrence after first time ablation according to body mass index:a nationwide Danish cohort study
- Author
-
Tønnesen, Jacob, Pallisgaard, Jannik, Ruwald, Martin H., Rasmussen, Peter Vibe, Johannessen, Arne, Hansen, Jim, Worck, Rene Husted, Zörner, Christopher R., Riis-Vestergaard, Lise, Middelfart, Charlotte, Gislason, Gunnar, Hansen, Morten Lock, Tønnesen, Jacob, Pallisgaard, Jannik, Ruwald, Martin H., Rasmussen, Peter Vibe, Johannessen, Arne, Hansen, Jim, Worck, Rene Husted, Zörner, Christopher R., Riis-Vestergaard, Lise, Middelfart, Charlotte, Gislason, Gunnar, and Hansen, Morten Lock
- Abstract
Aims Overweight is associated with increased risk of atrial fibrillation (AF), but the impact of overweight and AF recurrence after ablation is less clear. Despite this, an increasing number of AF ablations are carried out in overweight patients. We investigated the impact of body mass index (BMI) on AF recurrence rates after ablation. Methods and results Through Danish nationwide registers, all patients undergoing first-time AF ablation between 2010 and 2018 were identified. Exposure of interest was BMI. The primary outcome was recurrent AF, defined from either any usage of antiarrhythmic medication, AF hospitalization, cardioversion, or re-ablation. A total of 9188 patients were included. Median age and interquartile range was 64 (60–75) in the normal-weight group and 60 (53–66) in the morbidly obese. There was an increase in comorbidity burden with increasing BMI, including a higher prevalence of heart failure, chronic obstructive pulmonary disease, diabetes, and hypertension. At 1- and 5-year follow ups, recurrence rates of AF increased incrementally by BMI categories. The hazard ratios and 95% confidence intervals of recurrent AF after ablation were 1.15 (1.07–1.23), 1.18 (1.09–1.28), and 1.26 (1.13–1.41) in overweight, obese, and morbidly obese, respectively, compared with normal-weight patients. Procedure duration and X-ray dose exposure also increased with increasing BMI. Conclusion Following AF ablation, recurrence rates of AF increased incrementally with increasing BMI. Therefore, aggressive weight management pre ablation in overweight patients could potentially provide substantial benefits and improve short- and long-term outcomes after ablation., Aims: Overweight is associated with increased risk of atrial fibrillation (AF), but the impact of overweight and AF recurrence after ablation is less clear. Despite this, an increasing number of AF ablations are carried out in overweight patients. We investigated the impact of body mass index (BMI) on AF recurrence rates after ablation. Methods and results: Through Danish nationwide registers, all patients undergoing first-time AF ablation between 2010 and 2018 were identified. Exposure of interest was BMI. The primary outcome was recurrent AF, defined from either any usage of antiarrhythmic medication, AF hospitalization, cardioversion, or re-ablation. A total of 9188 patients were included. Median age and interquartile range was 64 (60-75) in the normal-weight group and 60 (53-66) in the morbidly obese. There was an increase in comorbidity burden with increasing BMI, including a higher prevalence of heart failure, chronic obstructive pulmonary disease, diabetes, and hypertension. At 1- and 5-year follow ups, recurrence rates of AF increased incrementally by BMI categories. The hazard ratios and 95% confidence intervals of recurrent AF after ablation were 1.15 (1.07-1.23), 1.18 (1.09-1.28), and 1.26 (1.13-1.41) in overweight, obese, and morbidly obese, respectively, compared with normal-weight patients. Procedure duration and X-ray dose exposure also increased with increasing BMI. Conclusion: Following AF ablation, recurrence rates of AF increased incrementally with increasing BMI. Therefore, aggressive weight management pre ablation in overweight patients could potentially provide substantial benefits and improve short- and long-term outcomes after ablation.
- Published
- 2023
22. Serial troponin-T and long-term outcomes in suspected acute coronary syndrome
- Author
-
Pareek, Manan, Kragholm, Kristian H., Kristensen, Anna Meta Dyrvig, Vaduganathan, Muthiah, Pallisgaard, Jannik L., Byrne, Christina, Biering-Sorensen, Tor, Lee, Christina Ji-Young, Bonde, Anders Nissen, Mortensen, Martin Bodtker, Maeng, Michael, Fosbol, Emil L., Kober, Lars, Olsen, Niels Thue, Gislason, Gunnar H., Bhatt, Deepak L., Torp-Pedersen, Christian, Pareek, Manan, Kragholm, Kristian H., Kristensen, Anna Meta Dyrvig, Vaduganathan, Muthiah, Pallisgaard, Jannik L., Byrne, Christina, Biering-Sorensen, Tor, Lee, Christina Ji-Young, Bonde, Anders Nissen, Mortensen, Martin Bodtker, Maeng, Michael, Fosbol, Emil L., Kober, Lars, Olsen, Niels Thue, Gislason, Gunnar H., Bhatt, Deepak L., and Torp-Pedersen, Christian
- Abstract
Background Long-term prognostic implications of serial high-sensitivity troponin concentrations in subjects with suspected acute coronary syndrome are unknown. Methods and results Individuals with a first diagnosis of myocardial infarction, unstable angina, observation for suspected myocardial infarction, or chest pain from 2012 through 2019 who underwent two high-sensitivity troponin-T (hsTnT) measurements 1-7 h apart were identified through Danish national registries. Absolute and relative risks for death at days 0-30 and 31-365, stratified for whether subjects had normal or elevated hsTnT concentrations, and whether these concentrations changed by 20 to 50%, or >50% in either direction from first to second measurement, were calculated through multivariable logistic regression with average treatment effect modeling. Of the 28 902 individuals included, 2.8% had died at 30 days, whereas 4.9% of those who had survived the first 30 days died between days 31-365. The standardized risk of death was highest among subjects with two elevated hsTnT concentrations (0-30 days: 4.3%, 31-365 days: 7.2%). In this group, mortality was significantly higher in those with a > 20 to 50% or >50% rise from first to second measurement, though only at 30 days. The risk of death was very low in subjects with two normal hsTnT concentrations (0-30 days: 0.1%, 31-365 days: 0.9%) and did not depend on relative or absolute changes between measurements. Conclusions Individuals with suspected acute coronary syndrome and two consecutively elevated hsTnT concentrations consistently had the highest risk of death. Mortality was very low in subjects with two normal hsTnT concentrations, irrespective of changes between measurements.
- Published
- 2023
23. Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation : nationwide cohort study
- Author
-
Staerk, Laila, Lip, Gregory Y H, Olesen, Jonas B, Fosbøl, Emil L, Pallisgaard, Jannik L, Bonde, Anders N, Gundlund, Anna, Lindhardt, Tommi B, Hansen, Morten L, Torp-Pedersen, Christian, and Gislason, Gunnar H
- Published
- 2015
24. Risk and timing of venous thromboembolism in patients with gastrointestinal cancer: a nationwide Danish cohort study
- Author
-
Tønnesen, Jacob, primary, Pallisgaard, Jannik, additional, Rasmussen, Peter Vibe, additional, Ruwald, Martin H, additional, Lamberts, Morten, additional, Nouhravesh, Nina, additional, Strange, Jarl, additional, Gislason, Gunnar Hilmar, additional, and Hansen, Morten Lock, additional
- Published
- 2023
- Full Text
- View/download PDF
25. Short- and long-term risk of atrial fibrillation recurrence after first time ablation according to body mass index: a nationwide Danish cohort study
- Author
-
Tønnesen, Jacob, primary, Pallisgaard, Jannik, additional, Ruwald, Martin H, additional, Rasmussen, Peter Vibe, additional, Johannessen, Arne, additional, Hansen, Jim, additional, Worck, Rene Husted, additional, Zörner, Christopher R, additional, Riis-Vestergaard, Lise, additional, Middelfart, Charlotte, additional, Gislason, Gunnar, additional, and Hansen, Morten Lock, additional
- Published
- 2022
- Full Text
- View/download PDF
26. Atrial fibrillation onset before heart failure or vice versa: what is worst? A nationwide register study
- Author
-
Pallisgaard, Jannik, primary, Greve, Anders M, additional, Lock-Hansen, Morten, additional, Thune, Jens Jakob, additional, Fosboel, Emil Loldrup, additional, Devereux, Richard B, additional, Okin, Peter M, additional, Gislason, Gunnar H, additional, Torp-Pedersen, Christian, additional, and Bang, Casper N, additional
- Published
- 2022
- Full Text
- View/download PDF
27. Serial troponin-T and long-term outcomes in suspected acute coronary syndrome
- Author
-
Pareek, Manan, primary, Kragholm, Kristian H, additional, Kristensen, Anna Meta Dyrvig, additional, Vaduganathan, Muthiah, additional, Pallisgaard, Jannik L, additional, Byrne, Christina, additional, Biering-Sørensen, Tor, additional, Lee, Christina Ji-Young, additional, Bonde, Anders Nissen, additional, Mortensen, Martin Bødtker, additional, Maeng, Michael, additional, Fosbøl, Emil L, additional, Køber, Lars, additional, Olsen, Niels Thue, additional, Gislason, Gunnar H, additional, Bhatt, Deepak L, additional, and Torp-Pedersen, Christian, additional
- Published
- 2022
- Full Text
- View/download PDF
28. Treatment patterns for oral anticoagulants in older patients with atrial fibrillation: a retrospective, cross-sectional, nationwide study from Denmark
- Author
-
Rasmussen, Peter Vibe, primary, Sakthivel, Tharsika, additional, Dalgaard, Frederik, additional, Gislason, Gunnar Hilmar, additional, Pallisgaard, Jannik Langtved, additional, and Hansen, Morten Lock, additional
- Published
- 2022
- Full Text
- View/download PDF
29. Abstract 15302: NOAC or VKA With Antiplatelets Following Myocardial Infarction or PCI in Atrial Fibrillation
- Author
-
Sindet-Pedersen, Caroline, Lamberts, Morten, Staerk, Laila, Nissen Bonde, Anders, Berger, Jeffrey S, Langtved Pallisgaard, Jannik, Hansen, Morten L, Torp-Pedersen, Christian, Gislason, Gunnar G, and Bjerring Olesen, Jonas
- Published
- 2017
30. PO-651-07 REPEATED ATRIAL FIBRILLATION ABLATIONS - A NATIONWIDE, REGISTRY-BASED DANISH STUDY
- Author
-
Tϕnnesen, Jacob, primary, Pallisgaard, Jannik Langtved, additional, Rasmussen, Peter Vibe, additional, Ruwald, Martin H., additional, Zörner, Christopher Ryan, additional, and Hansen, Morten L., additional
- Published
- 2022
- Full Text
- View/download PDF
31. Prognostic implications of serial high-sensitivity cardiac troponin testing among patients with COVID-19:A Danish nationwide registry-based cohort study
- Author
-
Polcwiartek, Christoffer, Krogager, Maria L, Andersen, Mikkel P, Butt, Jawad H, Pallisgaard, Jannik, Fosbøl, Emil, Schou, Morten, Bhatt, Deepak L, Singh, Avinainder, Køber, Lars, Gislason, Gunnar H, Bang, Casper N, Torp-Pedersen, Christian, Kragholm, Kristian, Pareek, Manan, Polcwiartek, Christoffer, Krogager, Maria L, Andersen, Mikkel P, Butt, Jawad H, Pallisgaard, Jannik, Fosbøl, Emil, Schou, Morten, Bhatt, Deepak L, Singh, Avinainder, Køber, Lars, Gislason, Gunnar H, Bang, Casper N, Torp-Pedersen, Christian, Kragholm, Kristian, and Pareek, Manan
- Abstract
BACKGROUND: Although troponin elevation is associated with worse outcomes among patients with coronavirus disease 2019 (COVID-19), prognostic implications of serial troponin testing are lacking. We investigated the association between serial troponin measurements and adverse COVID-19 outcomes.METHODS: Using Danish registries, we identified COVID-19 patients with a high-sensitivity troponin measurement followed by a second measurement within 1-24 h. All measurements during follow-up were also utilized in subsequent time-varying analyses. We assessed all-cause mortality associated with the absence/presence of myocardial injury (≥1 troponin measurement >99th percentile upper reference limit) and absence/presence of dynamic troponin changes (>20% relative change if first measurement elevated, >50% relative change if first measurement normal).RESULTS: Of 346 included COVID-19 patients, 56% had myocardial injury. Overall, 20% had dynamic troponin changes. In multivariable Cox regression models, myocardial injury was associated with all-cause mortality (HR = 2.56, 95%CI = 1.46-4.51), as were dynamic troponin changes (HR = 1.66, 95%CI = 1.04-2.64). We observed a low incidence of myocardial infarction (4%) and invasive coronary procedures (4%) among patients with myocardial injury.CONCLUSIONS: Myocardial injury and dynamic troponin changes determined using serial high-sensitivity troponin testing were associated with poor prognosis among patients with COVID-19. The risk of developing myocardial infarction requiring invasive management during COVID-19 hospitalization was low.
- Published
- 2022
32. Lung ultrasound findings in hospitalized COVID-19 patients in relation to venous thromboembolic events:the ECHOVID-19 study
- Author
-
Skaarup, Kristoffer Grundtvig, Lassen, Mats Christian Hojbjerg, Espersen, Caroline, Lind, Jannie Norgaard, Johansen, Niklas Dyrby, Sengeløv, Morten, Alhakak, Alia Saed, Nielsen, Anne Bjerg, Ravnkilde, Kirstine, Hauser, Raphael, Schops, Liv Borum, Holt, Eva, Bundgaard, Henning, Hassager, Christian, Jabbari, Reza, Carlsen, Jorn, Kirk, Ole, Bodtger, Uffe, Lindholm, Matias Greve, Wiese, Lothar, Kristiansen, Ole Peter, Walsted, Emil Schwarz, Nielsen, Olav Wendelboe, Lindegaard, Birgitte, Tonder, Niels, Jeschke, Klaus Nielsen, Ulrik, Charlotte Suppli, Lamberts, Morten, Sivapalan, Pradeesh, Pallisgaard, Jannik, Gislason, Gunnar, Iversen, Kasper, Jensen, Jens Ulrik Staehr, Schou, Morten, Skaarup, Soren Helbo, Platz, Elke, Biering-Sorensen, Tor, Skaarup, Kristoffer Grundtvig, Lassen, Mats Christian Hojbjerg, Espersen, Caroline, Lind, Jannie Norgaard, Johansen, Niklas Dyrby, Sengeløv, Morten, Alhakak, Alia Saed, Nielsen, Anne Bjerg, Ravnkilde, Kirstine, Hauser, Raphael, Schops, Liv Borum, Holt, Eva, Bundgaard, Henning, Hassager, Christian, Jabbari, Reza, Carlsen, Jorn, Kirk, Ole, Bodtger, Uffe, Lindholm, Matias Greve, Wiese, Lothar, Kristiansen, Ole Peter, Walsted, Emil Schwarz, Nielsen, Olav Wendelboe, Lindegaard, Birgitte, Tonder, Niels, Jeschke, Klaus Nielsen, Ulrik, Charlotte Suppli, Lamberts, Morten, Sivapalan, Pradeesh, Pallisgaard, Jannik, Gislason, Gunnar, Iversen, Kasper, Jensen, Jens Ulrik Staehr, Schou, Morten, Skaarup, Soren Helbo, Platz, Elke, and Biering-Sorensen, Tor
- Abstract
Purpose Several studies have reported thromboembolic events to be common in severe COVID-19 cases. We sought to investigate the relationship between lung ultrasound (LUS) findings in hospitalized COVID-19 patients and the development of venous thromboembolic events (VTE). Methods A total of 203 adults were included from a COVID-19 ward in this prospective multi-center study (mean age 68.6 years, 56.7% men). All patients underwent 8-zone LUS, and all ultrasound images were analyzed off-line blinded. Several LUS findings were investigated (total number of B-lines, B-line score, and LUS-scores). Results Median time from admission to LUS examination was 4 days (IQR: 2, 8). The median number of B-lines was 12 (IQR: 8, 18), and 44 (21.7%) had a positive B-line score. During hospitalization, 17 patients developed VTE (4 deep-vein thrombosis, 15 pulmonary embolism), 12 following and 5 prior to LUS. In fully adjusted multivariable Cox models (excluding participants with VTE prior to LUS), all LUS parameters were significantly associated with VTE (total number of B-lines: HR = 1.14, 95% CI (1.03, 1.26) per 1 B-line increase), positive B-line score: HR = 9.79, 95% CI (1.87, 51.35), and LUS-score: HR = 1.51, 95% CI (1.10, 2.07), per 1-point increase). The B-line score and LUS-score remained significantly associated with VTE in sensitivity analyses. Conclusion In hospitalized COVID-19 patients, pathological LUS findings were common, and the total number of B-lines, B-line score, and LUS-score were all associated with VTE. These findings indicate that the LUS examination may be useful in risk stratification and the clinical management of COVID-19. These findings should be considered hypothesis generating. Clinicaltrials.gov ID NCT04377035
- Published
- 2022
33. Treatment patterns for oral anticoagulants in older patients with atrial fibrillation:A retrospective, cross-sectional, nationwide study from Denmark
- Author
-
Rasmussen, Peter Vibe, Sakthivel, Tharsika, Dalgaard, Frederik, Gislason, Gunnar Hilmar, Pallisgaard, Jannik Langtved, Hansen, Morten Lock, Rasmussen, Peter Vibe, Sakthivel, Tharsika, Dalgaard, Frederik, Gislason, Gunnar Hilmar, Pallisgaard, Jannik Langtved, and Hansen, Morten Lock
- Abstract
Objectives Atrial fibrillation (AF) is a predominant risk factor of ischaemic stroke and treatment with oral anticoagulants (OACs) is recommended in all patients with risk factors. This study sought to examine treatment patterns of OACs in older patients with AF. Design Retrospective, cross-sectional study. Setting Danish nationwide administrative and clinical registers and databases. Participants A total of 40 027 patients, >75 years of age, after their first hospital contact due to AF between 2010 and 2018. Primary and secondary outcomes measures The primary event of interest was claimed prescriptions for OACs within 180 days after first hospital contact due to AF. Proportions of patients treated with OACs were estimated and clinical factors associated with the probability of receiving OAC treatment were identified using adjusted logistic regression models. Results A total of 40 027 patients were included with a slight majority of women (54%). The median age was 81 years (IQR 78-86). We found that an overall 32 235 patients (81%) were prescribed an OAC after their first hospital contact due to AF with a marked increase in the proportion of patients treated from 2010 to 2018. Factors related to a decreased probability of receiving treatment were bleeding risk factors such as a history of haemorrhagic stroke (OR 0.21, 95% CI 0.16 to 0.27), any bleeding (OR 0.58, 95% CI 0.53 to 0.62) as well as markers of frailty such as osteoporosis (OR 0.78, 95% CI 0.71 to 0.85). Conclusion In this large nationwide study, we found that in older patients with AF, the overall rates of OAC prescription were generally high (∼80%) and increasing during the last decade. Factors associated with not receiving guideline recommended OAC treatment were generally related to bleeding risk factors or frailty.
- Published
- 2022
34. Glycated haemoglobin levels among 3295 hospitalized COVID-19 patients, with and without diabetes, and risk of severe infection, admission to an intensive care unit and all-cause mortality
- Author
-
Alhakak, Amna, Butt, Jawad H., Gerds, Thomas A., Fosbol, Emil L., Mogensen, Ulrik M., Kroll, Johanna, Pallisgaard, Jannik L., Gislason, Gunnar H., Torp-Pedersen, Christian, Kober, Lars, Weeke, Peter E., Alhakak, Amna, Butt, Jawad H., Gerds, Thomas A., Fosbol, Emil L., Mogensen, Ulrik M., Kroll, Johanna, Pallisgaard, Jannik L., Gislason, Gunnar H., Torp-Pedersen, Christian, Kober, Lars, and Weeke, Peter E.
- Abstract
Aim To determine the risk of adverse outcomes across the spectrum of glycated haemoglobin (HbA1c) levels among hospitalized COVID-19 patients with and without diabetes. Materials and methods Danish nationwide registries were used to study the association between HbA1c levels and 30-day risk of all-cause mortality and the composite of severe COVID-19 infection, intensive care unit (ICU) admission and all-cause mortality. The study population comprised patients hospitalized with COVID-19 (3 March 2020 to 31 December 2020) with a positive polymerase chain reaction (PCR) test and an available HbA1c ≤ 6 months before the first positive PCR test. All patients had at least 30 days of follow-up. Among patients with diabetes, HbA1c was categorized as <48 mmol/mol, 48 to 53 mmol/mol, 54 to 58 mmol/mol, 59 to 64 mmol/mol (reference) and >64 mmol/mol. Among patients without diabetes, HbA1c was stratified into <31 mmol/mol, 31 to 36 mmol/mol (reference), 37 to 41 mmol/mol and 42 to 47 mmol/mol. Thirty-day standardized absolute risks and standardized absolute risk differences are reported. Results We identified 3295 hospitalized COVID-19 patients with an available HbA1c (56.2% male, median age 73.9 years), of whom 35.8% had diabetes. The median HbA1c was 54 and 37 mmol/mol among patients with and without diabetes, respectively. Among patients with diabetes, the standardized absolute risk difference of the composite outcome was higher with HbA1c < 48 mmol/mol (12.0% [95% confidence interval {CI} 3.3% to 20.8%]) and HbA1c > 64 mmol/mol (15.1% [95% CI 6.2% to 24.0%]), compared with HbA1c 59 to 64 mmol/mol (reference). Among patients without diabetes, the standardized absolute risk difference of the composite outcome was greater with HbA1c < 31 mmol/mol (8.5% [95% CI 0.5% to 16.5%]) and HbA1c 42 to 47 mmol/mol (6.7% [95% CI 1.3% to 12.1%]), compared with HbA1c 31 to 36 mmol/mol (reference). Conclusions Patients with COVID-1
- Published
- 2022
35. Treatment of older patients with atrial fibrillation by morbidity burden
- Author
-
Rasmussen, Peter Vibe, Pallisgaard, Jannik Langtved, Hansen, Morten Lock, Gislason, Gunnar Hilmar, Torp-Pedersen, Christian, Ruwald, Martin, Alexander, Karen P., Lopes, Renato D., Al-Khatib, Sana M., Dalgaard, Frederik, Rasmussen, Peter Vibe, Pallisgaard, Jannik Langtved, Hansen, Morten Lock, Gislason, Gunnar Hilmar, Torp-Pedersen, Christian, Ruwald, Martin, Alexander, Karen P., Lopes, Renato D., Al-Khatib, Sana M., and Dalgaard, Frederik
- Abstract
AIMS : Older patients with atrial fibrillation (AF) are at risk of adverse outcomes, which is accentuated by comorbidities. We sought to examine the association between morbidity burden and the treatment of older AF patients. METHODS AND RESULTS : Using Danish nationwide registers we included patients ≥70 years of age between 2010 and 2017 at their first hospitalization due to AF. Using multiple logistic regression models we examined the association between morbidity burden and the odds of receiving oral anticoagulants (OACs), anti-arrhythmic drugs (AADs), and rhythm-control procedures (direct current cardioversions and catheter ablations). A total of 48 995 patients were included with a majority of women (54%), with a median age of 80 years [interquartile range (IQR) 75-85], and a median morbidity burden of 2 comorbidities (IQR 1-3). Increasing morbidity burden was associated with decreasing odds of OAC treatment with patients having >5 comorbidities having the lowest odds [odds ratio (OR) 0.38, 95% confidence interval (CI) 0.35-0.42] compared to patients with low morbidity burden (0-1 comorbidities). Having >5 comorbidities were associated with increased odds of AAD treatment (OR 1.90, 95% CI 1.64-2.21) and decreased odds of AF procedures (OR 0.39, 95% CI 0.31-0.48), compared to patients with a low morbidity burden (0-1 comorbidities). Examining morbidity burden continuously revealed similar results. CONCLUSIONS : In older AF patients, multimorbidity was associated with lower odds of receiving OACs and rhythm-control procedures but increased odds of AADs. This presents a clinical conundrum as multimorbid patients potentially benefit the most from treatment with OACs.
- Published
- 2022
36. Gastrointestinal bleeding and the risk of colorectal cancer in anticoagulated patients with atrial fibrillation
- Author
-
Rasmussen, Peter Vibe, Dalgaard, Frederik, Gislason, Gunnar Hilmar, Brandes, Axel, Johnsen, Søren Paaske, Grove, Erik Lerkevang, Torp-Pedersen, Christian, Dybro, Lars, Harboe, Louise, Münster, Anna-Marie Bloch, Pedersen, Lasse, Blanche, Paul, Pallisgaard, Jannik Langtved, Hansen, Morten Lock, Rasmussen, Peter Vibe, Dalgaard, Frederik, Gislason, Gunnar Hilmar, Brandes, Axel, Johnsen, Søren Paaske, Grove, Erik Lerkevang, Torp-Pedersen, Christian, Dybro, Lars, Harboe, Louise, Münster, Anna-Marie Bloch, Pedersen, Lasse, Blanche, Paul, Pallisgaard, Jannik Langtved, and Hansen, Morten Lock
- Abstract
AIMS: Gastrointestinal bleeding (GI-bleeding) is frequent in patients with atrial fibrillation (AF) treated with oral anticoagulation (OAC) therapy. We sought to investigate to what extent lower GI-bleeding represents the unmasking of an occult colorectal cancer.METHODS AND RESULTS: A total of 125 418 Danish AF patients initiating OAC therapy were identified using Danish administrative registers. Non-parametric estimation and semi-parametric absolute risk regression were used to estimate the absolute risks of colorectal cancer in patients with and without lower GI-bleeding. During a maximum of 3 years of follow-up, we identified 2576 patients with lower GI-bleeding of whom 140 patients were subsequently diagnosed with colorectal cancer within the first year of lower GI-bleeding. In all age groups, we observed high risks of colorectal cancer after lower GI-bleeding. The absolute 1-year risk ranged from 3.7% [95% confidence interval (CI) 2.2-6.2] to 8.1% (95% CI 6.1-10.6) in the age groups ≤65 and 76-80 years of age, respectively. When comparing patients with and without lower GI-bleeding, we found increased risk ratios of colorectal cancer across all age groups with a risk ratio of 24.2 (95% CI 14.5-40.4) and 12.3 (95% CI 7.9-19.0) for the youngest and oldest age group of ≤65 and >85 years, respectively.CONCLUSION: In anticoagulated AF patients, lower GI-bleeding conferred high absolute risks of incident colorectal cancer. Lower GI-bleeding should not be dismissed as a benign consequence of OAC therapy but always examined for a potential underlying malignant cause.
- Published
- 2022
37. Short- and long-term risk of atrial fibrillation recurrence after first time ablation according to body mass index: a nationwide Danish cohort study.
- Author
-
Tønnesen, Jacob, Pallisgaard, Jannik, Ruwald, Martin H, Rasmussen, Peter Vibe, Johannessen, Arne, Hansen, Jim, Worck, Rene Husted, Zörner, Christopher R, Riis-Vestergaard, Lise, Middelfart, Charlotte, Gislason, Gunnar, and Hansen, Morten Lock
- Abstract
Aims Overweight is associated with increased risk of atrial fibrillation (AF), but the impact of overweight and AF recurrence after ablation is less clear. Despite this, an increasing number of AF ablations are carried out in overweight patients. We investigated the impact of body mass index (BMI) on AF recurrence rates after ablation. Methods and results Through Danish nationwide registers, all patients undergoing first-time AF ablation between 2010 and 2018 were identified. Exposure of interest was BMI. The primary outcome was recurrent AF, defined from either any usage of antiarrhythmic medication, AF hospitalization, cardioversion, or re-ablation. A total of 9188 patients were included. Median age and interquartile range was 64 (60–75) in the normal-weight group and 60 (53–66) in the morbidly obese. There was an increase in comorbidity burden with increasing BMI, including a higher prevalence of heart failure, chronic obstructive pulmonary disease, diabetes, and hypertension. At 1- and 5-year follow ups, recurrence rates of AF increased incrementally by BMI categories. The hazard ratios and 95% confidence intervals of recurrent AF after ablation were 1.15 (1.07–1.23), 1.18 (1.09–1.28), and 1.26 (1.13–1.41) in overweight, obese, and morbidly obese, respectively, compared with normal-weight patients. Procedure duration and X-ray dose exposure also increased with increasing BMI. Conclusion Following AF ablation, recurrence rates of AF increased incrementally with increasing BMI. Therefore, aggressive weight management pre ablation in overweight patients could potentially provide substantial benefits and improve short- and long-term outcomes after ablation. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
38. Atrial fibrillation onset before heart failure or vice versa: what is worst? A nationwide register study.
- Author
-
Pallisgaard, Jannik, Greve, Anders M, Lock-Hansen, Morten, Thune, Jens Jakob, Fosboel, Emil Loldrup, Devereux, Richard B, Okin, Peter M, Gislason, Gunnar H, Torp-Pedersen, Christian, and Bang, Casper N
- Abstract
Aims: Atrial fibrillation (AF) and heart failure (HF) often coexist. However, whether AF onset before HF or vice versa is associated with the worst outcome remains unclear. A consensus of large studies can guide future research and preventive strategies to better target high-risk patients.Methods and Results: We included all Danish cases with the coexistence of AF and HF (2005-17) using nationwide registries. Patients were divided into three separate groups (i) AF before HF, (ii) HF before AF, or (iii) AF and HF diagnosed concurrently (±30 days). Adjusting landmark Cox analyses (index date was the time of the latter diagnosis of AF or HF) were used for evaluating the association of the three groups with a composite outcome of ischaemic stroke or death. Among a total of 49 042 patients included, 40% had AF before HF, 27% had HF before AF, and 33% had AF and HF diagnosed concurrently. The composite endpoint accrued more often in patients with HF before AF compared to the two other groups (<0.001), and this remained significant in the adjusted analyses with hazard ratios (95% confidence intervals) of 1.26 (1.22-1.30) compared to AF before HF. Finally, antihypertensive treatment, oral anticoagulants, amiodarone, statins, and AF ablation were associated with a lower hazard ratio of the composite endpoint (all < 0.001).Conclusions: In this large Danish national cohort, diagnosis of HF before AF was associated with an increased absolute risk of death compared to AF before HF and AF and HF diagnosed concurrently. Antihypertensive treatment, oral anticoagulants, amiodarone, statins, and AF ablation may improve prognosis. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
39. Prognostic implications of serial high-sensitivity cardiac troponin testing among patients with COVID-19: A Danish nationwide registry-based cohort study
- Author
-
Polcwiartek, Christoffer, primary, Krogager, Maria L., additional, Andersen, Mikkel P., additional, Butt, Jawad H., additional, Pallisgaard, Jannik, additional, Fosbøl, Emil, additional, Schou, Morten, additional, Bhatt, Deepak L., additional, Singh, Avinainder, additional, Køber, Lars, additional, Gislason, Gunnar H., additional, Bang, Casper N., additional, Torp-Pedersen, Christian, additional, Kragholm, Kristian, additional, and Pareek, Manan, additional
- Published
- 2022
- Full Text
- View/download PDF
40. Glycated haemoglobin levels among 3295 hospitalized COVID‐19 patients, with and without diabetes, and risk of severe infection, admission to an intensive care unit and all‐cause mortality
- Author
-
Alhakak, Amna, primary, Butt, Jawad H., additional, Gerds, Thomas A., additional, Fosbøl, Emil L., additional, Mogensen, Ulrik M., additional, Krøll, Johanna, additional, Pallisgaard, Jannik L., additional, Gislason, Gunnar H., additional, Torp‐Pedersen, Christian, additional, Køber, Lars, additional, and Weeke, Peter E., additional
- Published
- 2021
- Full Text
- View/download PDF
41. Risk of atrial fibrillation in diabetes mellitus: A nationwide cohort study
- Author
-
Pallisgaard, Jannik L, Schjerning, Anne-Marie, Lindhardt, Tommi B, Procida, Kristina, Hansen, Morten L, Torp-Pedersen, Christian, and Gislason, Gunnar H
- Published
- 2016
- Full Text
- View/download PDF
42. A risk score for predicting 30-day mortality in heart failure patients undergoing non-cardiac surgery
- Author
-
Andersson, Charlotte, Gislason, Gunnar H., Hlatky, Mark A., Sndergaard, Kathrine Bach, Pallisgaard, Jannik, Smith, Gustav J., Vasan, Ramachandran S., Larson, Martin G., Jensen, Per Fge, Kber, Lars, and Torp-Pedersen, Christian
- Published
- 2014
- Full Text
- View/download PDF
43. Lung ultrasound findings in hospitalized COVID-19 patients in relation to venous thromboembolic events: the ECHOVID-19 study
- Author
-
Skaarup, Kristoffer Grundtvig, primary, Lassen, Mats Christian Højbjerg, additional, Espersen, Caroline, additional, Lind, Jannie Nørgaard, additional, Johansen, Niklas Dyrby, additional, Sengeløv, Morten, additional, Alhakak, Alia Saed, additional, Nielsen, Anne Bjerg, additional, Ravnkilde, Kirstine, additional, Hauser, Raphael, additional, Schöps, Liv Borum, additional, Holt, Eva, additional, Bundgaard, Henning, additional, Hassager, Christian, additional, Jabbari, Reza, additional, Carlsen, Jørn, additional, Kirk, Ole, additional, Bodtger, Uffe, additional, Lindholm, Matias Greve, additional, Wiese, Lothar, additional, Kristiansen, Ole Peter, additional, Walsted, Emil Schwarz, additional, Nielsen, Olav Wendelboe, additional, Lindegaard, Birgitte, additional, Tønder, Niels, additional, Jeschke, Klaus Nielsen, additional, Ulrik, Charlotte Suppli, additional, Lamberts, Morten, additional, Sivapalan, Pradeesh, additional, Pallisgaard, Jannik, additional, Gislason, Gunnar, additional, Iversen, Kasper, additional, Jensen, Jens Ulrik Stæhr, additional, Schou, Morten, additional, Skaarup, Søren Helbo, additional, Platz, Elke, additional, and Biering-Sørensen, Tor, additional
- Published
- 2021
- Full Text
- View/download PDF
44. Significance of early recurrence of atrial fibrillation after catheter ablation:a nationwide Danish cohort study
- Author
-
Hodges, Gethin, Bang, Casper N., Torp-Pedersen, Christian, Hansen, Morten Lock, Schjerning, Anne Marie, Hansen, Jim, Johannessen, Arne, Gislason, Gunnar H., Pallisgaard, Jannik, Hodges, Gethin, Bang, Casper N., Torp-Pedersen, Christian, Hansen, Morten Lock, Schjerning, Anne Marie, Hansen, Jim, Johannessen, Arne, Gislason, Gunnar H., and Pallisgaard, Jannik
- Abstract
Background: Recurrence of atrial tachyarrhythmias after ablation of atrial fibrillation (AF) is common, although consensus guidelines advise against immediate re-ablation of “early recurrences” (occurring ≤ 90 days after ablation). However, recent studies show early recurrence is associated with “late recurrence” (occurring > 90 days) and question the duration of this “blanking period.” We investigated incidence and timing of early recurrence in relation to late recurrence in a large nationwide cohort. Methods: From Danish nationwide registers, we included all patients aged 18 and older who underwent first-time ablation for AF between January 2005 and April 2017 and followed them for up to 2 years. Results: Of the total 7339 patients included (72% male; median age 62 years), 2801 (38%) experienced early recurrence. The odds of late recurrence were 2.34 times higher (95% confidence interval, 2.09–2.63; P < 0.001) given early recurrence, compared with those without early recurrence. In particular, both timing and frequency of early recurrences were associated with a significantly higher odds of late recurrence in a graded relationship: odds ratio (OR) 2.08/4.96/6.25 for early recurrences in the first/second/third month respectively (all P < 0.001); and OR 1.64/2.83/5.14 for those experiencing one/two/more than two episodes respectively (all P < 0.001); compared with those without early recurrence. Conclusion: In patients undergoing first-time ablation for AF, both the frequency and later onset of early recurrence are significantly associated with higher odds of late recurrence. This suggests the arbitrary blanking period should be abandoned in favor of a case-by-case assessment when evaluating candidates for re-ablation.
- Published
- 2021
45. Hematuria and urinary tract cancers in patients with atrial fibrillation treated with oral anticoagulants
- Author
-
Rasmussen, Peter Vibe, Dalgaard, Frederik, Gislason, Gunnar Hilmar, Brandes, Axel, Johnsen, Søren Paaske, Grove, Erik Lerkevang, Torp-Pedersen, Christian, Münster, Anne-Marie Bloch, Erikson, Marie Schmidt, Pallisgaard, Jannik Langtved, Blanche, Paul, Hansen, Morten Lock, Rasmussen, Peter Vibe, Dalgaard, Frederik, Gislason, Gunnar Hilmar, Brandes, Axel, Johnsen, Søren Paaske, Grove, Erik Lerkevang, Torp-Pedersen, Christian, Münster, Anne-Marie Bloch, Erikson, Marie Schmidt, Pallisgaard, Jannik Langtved, Blanche, Paul, and Hansen, Morten Lock
- Abstract
AIMS: Patients with atrial fibrillation (AF) treated with oral anticoagulants (OAC) have an increased risk of bleeding including hematuria. In the general population gross hematuria is associated with urinary tract cancer. Consequently, we aimed to investigate the potential association between gross hematuria and urinary tract cancer in anticoagulated patients with AF.METHODS AND RESULTS: Using Danish nationwide registers, we included Danish AF patients treated with OACs between 2001 and 2016. Non-parametric estimation and semi-parametric absolute risk regression were used to estimate the absolute risk of urinary tract cancer in patients with- and without gross hematuria. We included 125,063 AF patients with a median age of 74 years (interquartile range [IQR] 65-80) and a majority of males (57%). The absolute risk of gross hematuria 12 months after treatment initiation increased with age ranging from 0.37% (95% Confidence Interval [CI] 0.31 - 0.42) to 0.85% (95% CI 0.75 - 0.96) in the youngest and oldest age groups of ≤ 70 years and > 80 years of age, respectively. The 1-year risk of urinary tract cancer after hematuria ranged from 4.2% (95% CI 2.6-6.6) to 6.5% (95% CI 4.6-9.0) for patients in age group > 80 years and 71-80 years, respectively. Gross hematuria conferred large risk ratios of urinary tract cancer when comparing patients with- and without hematuria across all age groups.CONCLUSION: Gross hematuria was associated with clinically relevant risks of urinary tract cancer in anticoagulated patients with AF. Thus, underlining the importance of meticulously examining anticoagulated patients with hematuria.
- Published
- 2021
46. Myocardial Impairment and Acute Respiratory Distress Syndrome in Hospitalized Patients With COVID-19:The ECHOVID-19 Study
- Author
-
Skaarup, Kristoffer Grundtvig, Højbjerg Lassen, Mats Christian, Lind, Jannie Nørgaard, Alhakak, Alia Saed, Sengeløv, Morten, Nielsen, Anne Bjerg, Espersen, Caroline, Hauser, Raphael, Schöps, Liv Borum, Holt, Eva, Johansen, Niklas Dyrby, Modin, Daniel, Sharma, Shreeya, Graff, Claus, Bundgaard, Henning, Hassager, Christian, Jabbari, Reza, Lebech, Anne-Mette, Kirk, Ole, Bødtger, Uffe, Lindholm, Matias Greve, Joseph, Gowsini, Wiese, Lothar, Schiødt, Frank Vinholt, Kristiansen, Ole Peter, Walsted, Emil Schwarz, Nielsen, Olav Wendelboe, Madsen, Birgitte Lindegaard, Tønder, Niels, Benfield, Thomas Lars, Jeschke, Klaus Nielsen, Ulrik, Charlotte Suppli, Knop, Filip, Pallisgaard, Jannik, Lamberts, Morten, Sivapalan, Pradeesh, Gislason, Gunnar, Solomon, Scott D., Iversen, Kasper, Stæhr Jensen, Jens Ulrik, Schou, Morten, and Biering-Sørensen, Tor
- Subjects
COVID-19 - Published
- 2020
47. Catheter ablation for atrial fibrillation is associated with lower incidence of heart failure and death
- Author
-
Modin, Daniel, Claggett, Brian, Gislason, Gunnar, Hansen, Morten Lock, Worck, Rene, Johannessen, Arne, Hansen, Jim, Svendsen, Jesper Hastrup, Pallisgaard, Jannik L, Schou, Morten, Køber, Lars, Solomon, Scott D, Torp-Pedersen, Christian, Biering-Sørensen, Tor, Modin, Daniel, Claggett, Brian, Gislason, Gunnar, Hansen, Morten Lock, Worck, Rene, Johannessen, Arne, Hansen, Jim, Svendsen, Jesper Hastrup, Pallisgaard, Jannik L, Schou, Morten, Køber, Lars, Solomon, Scott D, Torp-Pedersen, Christian, and Biering-Sørensen, Tor
- Abstract
AIMS: Catheter ablation for atrial fibrillation (CAF) improves symptoms, but whether CAF improves outcome is less clear. The purpose of this study was to investigate whether CAF is associated with improved outcome in atrial fibrillation (AF) patients with previous direct current (DC) cardioversion.METHODS AND RESULTS: We performed a nationwide cohort study including all patients who underwent their 1st direct current cardioversion for AF in the period 2003-15 (N = 25 439). End points were all-cause death, cardiovascular death, stroke/thromboembolism, and incident heart failure (HF). Catheter ablation for AF was treated as a time-varying covariate and the association with outcome was assessed using Cox regression. We also constructed a propensity-matched cohort and assessed the association between CAF and outcome. Median follow-up was 5.3 years (inter-quartile range 3.0-8.7 years). A total of 3509 patients (13.8%) underwent CAF during the study period. Following adjustment for age, gender, comorbidities, medications, educational level, household income, and CHA2DS2VASc score, CAF was associated with reduced risks of all-cause death, cardiovascular death, and incident HF [all-cause death: hazard ratio (HR) 0.69, P < 0.001; cardiovascular death: HR 0.68, P = 0.003; incident HF: HR 0.76, P = 0.011]. Catheter ablation for AF was not associated with a reduced risk of stroke/thromboembolism. These results were replicated in a propensity-matched cohort.CONCLUSION: In AF patients with a prior DC cardioversion, CAF was associated with a reduced risk of all-cause and cardiovascular death. This may be due to a reduced risk of HF.
- Published
- 2020
48. Management of Atrial Fibrillation in Older Patients by Morbidity Burden:Insights From Get With The Guidelines-Atrial Fibrillation
- Author
-
Dalgaard, Frederik, Xu, Haolin, Matsouaka, Roland A, Russo, Andrea M, Curtis, Anne B, Rasmussen, Peter Vibe, Ruwald, Martin H, Fonarow, Gregg C, Lowenstern, Angela, Hansen, Morten L, Pallisgaard, Jannik L, Alexander, Karen P, Alexander, John H, Lopes, Renato D, Granger, Christopher B, Lewis, William R, Piccini, Jonathan P, Al-Khatib, Sana M, Dalgaard, Frederik, Xu, Haolin, Matsouaka, Roland A, Russo, Andrea M, Curtis, Anne B, Rasmussen, Peter Vibe, Ruwald, Martin H, Fonarow, Gregg C, Lowenstern, Angela, Hansen, Morten L, Pallisgaard, Jannik L, Alexander, Karen P, Alexander, John H, Lopes, Renato D, Granger, Christopher B, Lewis, William R, Piccini, Jonathan P, and Al-Khatib, Sana M
- Abstract
Background Knowledge is scarce regarding how multimorbidity is associated with therapeutic decisions regarding oral anticoagulants (OACs) in patients with atrial fibrillation. Methods and Results We conducted a cross-sectional study of hospitalized patients with atrial fibrillation using the Get With The Guidelines-Atrial Fibrillation registry from 2013 to 2019. We identified patients ≥65 years and eligible for OAC therapy. Using 16 available comorbidity categories, patients were stratified by morbidity burden. A multivariable logistic regression model was used to determine the odds of receiving OAC prescription at discharge by morbidity burden. We included 34 174 patients with a median (interquartile range) age of 76 (71-83) years, 56.6% women, and 41.9% were not anticoagulated at admission. Of these patients, 38.6% had 0 to 2 comorbidities, 50.7% had 3 to 5 comorbidities, and 10.7% had ≥6 comorbidities. The overall discharge OAC prescription was high (85.6%). The prevalence of patients with multimorbidity increased from 59.7% in 2014 to 64.3% in 2019 (P trend=0.002). Using 0 to 2 comorbidities as the reference, the adjusted odds ratio (95% CI) of OAC prescription were 0.93 (0.82, 1.05) for patients with 3 to 5 comorbidities and 0.72 (0.60, 0.86) for patients with ≥6 comorbidities. In those with ≥6 comorbidities, the most common reason for nonprescription of OACs were frequent falls/frailty (31.0%). Conclusions In a contemporary quality-of-care database of hospitalized patients with atrial fibrillation eligible for OAC therapy, multimorbidity was common. A higher morbidity burden was associated with a lower odds of OAC prescription. This highlights the need for interventions to improve adherence to guideline-recommended anticoagulation in multimorbid patients with atrial fibrillation.
- Published
- 2020
49. Association between biomarkers and COVID-19 severity and mortality:A nationwide Danish cohortstudy
- Author
-
Hodges, Gethin, Pallisgaard, Jannik, Schjerning Olsen, Anne Marie, McGettigan, Patricia, Andersen, Mikkel, Krogager, Maria, Kragholm, Kristian, Køber, Lars, Gislason, Gunnar Hilmar, Torp-Pedersen, Christian, Bang, Casper N., Hodges, Gethin, Pallisgaard, Jannik, Schjerning Olsen, Anne Marie, McGettigan, Patricia, Andersen, Mikkel, Krogager, Maria, Kragholm, Kristian, Køber, Lars, Gislason, Gunnar Hilmar, Torp-Pedersen, Christian, and Bang, Casper N.
- Abstract
Objective To evaluate the association between common biomarkers, death and intensive care unit(ICU) admission in patients with COVID-19. Design Retrospective cohort study. From electronic national registry data, we used Cox analysis and bootstrapping to evaluate associations between baselinelevels of biomarkers and standardised absolute risks of death/ICU admission, adjusted for age and gender. Setting All hospitals in Denmark. Participants 1310 patients aged ≥18 years admitted to hospital with COVID-19 from 27th of February to 1st of May 2020, with available biochemistry data. Main outcome measures A composite of death/ICU admission occurring within 30 days. Results Of the 1310 patients admitted to hospital (54.6% men; median age 73.6 years), 352 (26.9%) experienced the composite endpoint and 263 (20.1%) died. For the composite endpoint, the absolute risks for moderately and severely elevated C reactive protein (CRP) were significantly higher, 21.5% and 39.2%, respectively, compared with 5.0% for those with normal CRP. Moderately and severely elevated leucocytes were significantly higher, 34.5% and 46.6% risk, respectively, compared with 23.2% for those with normal leucocytes. Moderately and severely decreased estimated glomerular filtration rates (eGFR) were significantly higher, 41.5% and 45.9% risk, respectively, compared with 30.4% for those with normal/mildly decreased eGFR. Normal and elevated ureas were significantly higher, 22.3% and 40.6% risk, respectively, compared with 7.3% for those with low urea. Elevated D-dimer was significantly higher, 31.8% risk, compared with 17.5% for those with normal D-dimer. Moderately and severely elevatedtroponins were significantly higher, 27.7% and 57.3% risk, respectively, compared with 9.4% for those with normal troponin. Elevated procalcitonin was significantly higher, 52.1% risk, compared with28.0% for those with normal procalcitonin. Conclusion In this nationwide study of patients admittedwith COVID-19, elevated l
- Published
- 2020
50. Risk factors and a 3-month risk score for predicting pacemaker implantation in patients with atrial fibrillations
- Author
-
Dalgaard, Frederik, Pallisgaard, Jannik Langtved, Lindhardt, Tommi Bo, Gislason, Gunnar, Blanche, Paul, Torp-Pedersen, Christian, Ruwald, Martin H, Dalgaard, Frederik, Pallisgaard, Jannik Langtved, Lindhardt, Tommi Bo, Gislason, Gunnar, Blanche, Paul, Torp-Pedersen, Christian, and Ruwald, Martin H
- Abstract
Objectives: To identify risk factors and to develop a predictive risk score for pacemaker implantation in patients with atrial fibrillation (AF).Methods: Using Danish nationwide registries, patients with newly diagnosed AF from 2000 to 2014 were identified. Cox proportional-hazards regression computed HRs for risk factors of pacemaker implantation. A logistic regression was used to fit a prediction model for 3-month risk of pacemaker implantation and derived a risk score using 80% of the data and its predictive accuracy estimated using the remaining 20%.Results: Among 155 934 AF patients included, the median age (IQR) was 75 (65-83) and 51.3% were men. During a median follow-up time of 3.4 (1.2-5.0) years, 8348 (5.4%) patients received a pacemaker implantation. Risk factors of pacemaker implantation were (in order of highest risk first) age above 60 years, congenital heart disease, heart failure at age under 60 years, prior syncope, valvular AF, hypertension, ischaemic heart disease, male sex and diabetes mellitus. The derived risk score assigns points ranging from 1 to 14 to each of these risk factors. The 3-month risk of pacemaker implantation increased from 0.4% (95% CI: 0.2 to 0.8) at 1 point to 2.6% (95% CI: 1.9 to 3.6) at 18 points. Area under the receiver operator characteristics curve was 62.9 (95% CI: 60.3 to 65.5).Conclusion: We highlighted risk factors of pacemaker implantation in newly diagnosed AF patients and created a risk score. The clinical utility of the risk score needs further investigation.
- Published
- 2020
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.